Pierre Heimann
Overview
Explore the profile of Pierre Heimann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
510
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Harb M, Abrassart T, Dewispeleare L, Sidon P, Dirckx N, Trepant A, et al.
Diagn Pathol
. 2025 Jan;
20(1):6.
PMID: 39810204
Background: Synchronous malignant histiocytoses are rare conditions that occur concurrently with another hematologic neoplasm. Most reported cases are associated with B-cell lymphoproliferative disorders, while associations with T-cell hemopathies are less...
2.
Wery A, Salaroli A, Andreozzi F, Paesmans M, Dewispelaere L, Heimann P, et al.
Ann Hematol
. 2024 Oct;
103(11):4671-4685.
PMID: 39365357
Patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) who undergo allogeneic hematopoietic stem-cell transplantation (alloHSCT) can have divergent survival outcomes while all in morphological complete remission (CR). Techniques...
3.
Goldman S, Bron D, Tousseyn T, Vierasu I, Dewispelaere L, Heimann P, et al.
Front Med (Lausanne)
. 2021 Dec;
8:798095.
PMID: 34901098
Since nucleoside-modified mRNA vaccines strongly activate T follicular helper cells, it is important to explore the possible impact of approved SARS-CoV-2 mRNA vaccines on neoplasms affecting this cell type. Herein,...
4.
Castiaux J, Vandernoot I, Dallemagne J, Bruneau M, Delaunoy M, Peyrassol X, et al.
Clin Lymphoma Myeloma Leuk
. 2021 May;
21(8):e645-e648.
PMID: 34049842
No abstract available.
5.
Kamel O, Rozen L, Lecomte S, Heimann P, Demulder A
Int J Lab Hematol
. 2021 Mar;
43(4):O211-O213.
PMID: 33759346
No abstract available.
6.
Carpentier C, Schandene L, Dewispelaere L, Heimann P, Cogan E, Roufosse F
J Allergy Clin Immunol Pract
. 2021 Feb;
9(6):2426-2439.e7.
PMID: 33545400
Background: Identification of patients with lymphocytic variant hypereosinophilic syndrome (L-HES) is challenging, and has important prognostic and therapeutic implications. Objective: This study was undertaken to assess diagnostic tools for L-HES...
7.
Carpentier C, Verbanck S, Schandene L, Heimann P, Trepant A, Cogan E, et al.
Front Immunol
. 2020 Aug;
11:1765.
PMID: 32849632
Lymphocytic variant hypereosinophilic syndrome is characterized by marked over-production of eosinophilopoietic factor(s) by dysregulated T cells leading to eosinophil expansion. In most cases, these T cells are clonal and express...
8.
Heimann P, Dewispelaere L
Curr Opin Oncol
. 2020 Jul;
32(5):391-397.
PMID: 32675596
Purpose Of Review: In this study, we will give an overview on the current and foreseeable indications of next-generation sequencing (NGS)-based technologies for the diagnosis, prognostic assessment and decision of...
9.
Dewispelaere L, Bleret L, Van Acker T, Van Branteghem C, Cochaux P, Heimann P, et al.
J Mol Diagn
. 2020 Jun;
22(8):1008-1019.
PMID: 32540368
With the improvement of treatment methods in acute hematology malignancies, the development of sensitive tools for minimal residual disease assessment has become a priority. The monitoring of WT1 expression level...
10.
Seremet T, Jansen Y, Planken S, Njimi H, Delaunoy M, El Housni H, et al.
J Transl Med
. 2019 Sep;
17(1):303.
PMID: 31488153
Background: Treatment with anti-PD1 monoclonal antibodies improves the survival of metastatic melanoma patients but only a subgroup of patients benefits from durable disease control. Predictive biomarkers for durable benefit could...